Рейши полисахарид порошок

Reishi; Reishi Polysaccharide; Ganoderma Lucidum; Ganoderma Lucidum: Latin Reishi: Japanese Magic Mushroom: Chinese Reishi: CommonSpecification & analysis: Source: By Hot water extract from mycelia of Reishi Mycelia, Precipitate with ethanol. Description: Brown powder with characteristic order and taste Excipient: No Particle size: 40-80mesh Standard: Q/Z008-2007 U. S. FDA Registration Number: 17217333984 Polysaccharides: More than 50% Protein: More than 15.0% Moisture: Less than 8% Ash: Less than 8%Remainder: Contamination free, 100% purity Microbiology and Heavy Metals: Total Plate Count: Less than 1000cfu/g Total Coliform: 30MPN/100g Count Yeast and Mold: 10cfu/g Pb: Less than 2.0mg/Kg As: Less than 1.0mg/Kg Hg: Less than 0.2mg/Kg Salmonella: NegativeActive constituents Polysaccharide and Protein Pharmacological and Clinical ResearchTraditional Chinese medicine focuses on an active health promotion for disease prevention. As a royal herb of ancient China and "Mushrooms of Immortality", Reishi has been used for the purpose of health promotion in China and other Asian countries for 2, 000 years.Though so far there have been no published clinical studies in humans to date for Reishi to treat cancers, but the indications for its supplemental use can be "indirectly" supported by the trials with other comparable mushroom polysaccharides for example the PSP and PSK (Chang 1994. )As a supplement for cancer patients, Reishi can reduce side effects of cytotoxic cancer therapy or radiotherapy and reduce the pain. It also has significant efficacy on anti-fatigue, hair loss and bone marrow suppression.Its immune stimulating properties, especially the activation of NK and CTL, are beneficial to the prevention of occurrence or recurrence of cancers via enhanced immune system defense. When administered orally, Reishi polysaccharides have demonstrated to enhance NK and CTL activity.The use of Reishi as a supplement to cancers, the recommended daily dose would be 5-10grams of its fruit body extract or equivalent.